his dataset supports a real-world pharmacovigilance study that evaluates and compares adverse events (AEs) associated with five biologics—efgartigimod, rozanolixizumab, eculizumab, ravulizumab, and zi
Tafamidis emerged as the first FDA-approved drug for treating termed amyloid fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second quarter (Q2) of 2019 to the f
The Eastern Europe Drug Safety Solutions And Pharmacovigilance report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic in
